शेयर बाज़ार का ज्ञान

Six manufacturing units, 700-plus regulatory filings, biosimilar clinical trials underway and a revenue model built on one principle: each new registration can potentially contribute USD 1.5 to 2 million in annual revenue. The potential compounding from that model is what has driven the stock and what investors need to understand before drawing conclusions about the current price.

Three businesses, one record quarter. But the oil division margin that drove the headline needs to be read carefully before drawing conclusions about what is sustainable.

Eight consecutive quarters of operational improvement. Revenue has already crossed its earlier three-year doubling target, nearly a year ahead of schedule, while management has now set its sights on Rs 3,200 crore of revenue by FY29. The opportunity is increasingly being shaped by higher-value programmes across industrial, mobility, aerospace, clean energy and semiconductor equipment.